These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18508484)

  • 1. Her2 cross talk and therapeutic resistance in breast cancer.
    Bender LM; Nahta R
    Front Biosci; 2008 May; 13():3906-12. PubMed ID: 18508484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.
    Collins DC; Cocchiglia S; Tibbitts P; Solon G; Bane FT; McBryan J; Treumann A; Eustace A; Hennessy B; Hill AD; Young LS
    Oncogene; 2015 Jan; 34(4):525-30. PubMed ID: 24469058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
    Nahta R
    Curr Med Chem; 2012; 19(7):1065-75. PubMed ID: 22229414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
    Mukohara T
    Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab resistance: role for Notch signaling.
    Mehta K; Osipo C
    ScientificWorldJournal; 2009 Dec; 9():1438-48. PubMed ID: 20024517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
    Gajria D; Chandarlapaty S
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
    Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
    Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 therapy: molecular mechanisms of trastuzumab resistance.
    Nahta R; Esteva FJ
    Breast Cancer Res; 2006; 8(6):215. PubMed ID: 17096862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Nahta R; Yuan LX; Du Y; Esteva FJ
    Mol Cancer Ther; 2007 Feb; 6(2):667-74. PubMed ID: 17308062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.